A mother battling a terminal illness successfully raised over £50,000 from the public by appealing for financial support to access the life-prolonging Enhertu drug. Jess Duggan, aged 44, expressed her gratitude for the overwhelming support she received, describing it as extraordinary. With the raised funds, she was able to undergo her first dose of the treatment privately, allowing her to mark her daughter’s 16th birthday and eagerly anticipate her son’s upcoming 13th birthday.
The denied access to the Enhertu drug, a critical treatment for women with breast cancer in various parts of the UK, has sparked public outrage. Jess’s situation highlights the disparity in access to this vital medication, which is available for free in Scotland and several other European countries. A recent survey by Breast Cancer Now revealed that an overwhelming 82% of UK adults believe that this life-prolonging drug should be accessible through the NHS for those in need.
Despite facing a dire prognosis of six weeks left to live due to her metastatic breast cancer, Jess remains resilient in advocating for NHS funding for the drug. She commended the generosity of strangers who contributed to her cause, emphasizing the urgent need for accessible healthcare options. Jess is urging the new Health Secretary to prioritize the funding of Enhertu to provide hope for patients in similar circumstances.
Jess’s journey highlights the emotional toll of navigating treatment options and financial burdens associated with life-threatening illnesses. Her determination to access the drug underscores the pressing need for equitable healthcare access for all patients. The ongoing petition, supported by various organizations, aims to expedite the availability of Enhertu for individuals facing similar challenges, emphasizing the urgency of the situation.
The National Institute for Health and Care Excellence (NICE) acknowledged the cost-effectiveness concerns surrounding Enhertu but indicated ongoing discussions to reach a viable solution. Jess’s story sheds light on the complexities of healthcare decision-making and the profound impact on individuals battling terminal illnesses.
